ETON
Eton Pharmaceuticals Inc
NASDAQ · Pharmaceuticals
$14.76
+0.41 (+2.86%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 40.40M | 33.29M | 123.87M | 122.17M | 107.30M |
| Net Income | -3,958,268 | -2,935,674 | 16.69M | 16.25M | 12.60M |
| EPS | — | — | — | — | — |
| Profit Margin | -9.8% | -9.3% | 13.5% | 13.3% | 11.8% |
| Rev Growth | +21.4% | +21.4% | -9.3% | -8.5% | +2.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 108.78M | 108.78M | 22.18M | 24.71M | 28.65M |
| Total Equity | 89.13M | 89.13M | 143.30M | 125.41M | 143.27M |
| D/E Ratio | 1.22 | 1.22 | 0.15 | 0.20 | 0.20 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -1,501,782 | -1,175,684 | 22.30M | 25.36M | 21.76M |
| Free Cash Flow | — | — | 13.57M | 11.15M | 16.18M |